{"article_title": "Zogenix: Time to Buy This Battleground Stock? -- The Motley Fool", "article_keywords": ["fool", "buy", "version", "motley", "zohydro", "share", "tremendous", "good", "video", "tamperresistant", "usage", "williamson", "battleground", "zogenix", "stock"], "article_url": "http://www.fool.com/investing/general/2014/07/10/zogenix-time-to-buy-this-battleground-stock.aspx", "article_text": "Zogenix (NASDAQ:ZGNX) shareholders have had a roller coaster ride in 2014, with the share price climbing to almost $5 per share before cratering below $1.70. Tremendous controversy has swirled around Zohydro ER, an opioid painkiller that many fear could be abused.\n\nThe company received good news when Massachusetts Governor Deval Patrick's regulations to restrict the drug's usage were overturned by a federal court, and announced further good news that it may have a more tamper-resistant version of the drug out by 2015.\n\nThe big question: Has all the negativity been priced in already, or is this stock still one to avoid? In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.", "article_metadata": {"publish_time": "17:00", "description": "Controversy keeps swirling around Zogenix.", "ResponsiveALP": "1Ses_control-21_control_100", "author": "Michael Douglass and Dave Williamson", "promo": "Controversy keeps swirling around Zogenix.", "twitter": {"title": "Zogenix: Time to Buy This Battleground Stock? --  The Motley Fool", "description": "Controversy keeps swirling around Zogenix.", "site": "@themotleyfool"}, "msvalidate.01": "8D40D58712924715BAA79D135A6C8DDA", "og": {"site_name": "The Motley Fool", "description": "Controversy keeps swirling around Zogenix.", "title": "Zogenix: Time to Buy This Battleground Stock? --  The Motley Fool", "url": "http://www.fool.com/investing/general/2014/07/10/zogenix-time-to-buy-this-battleground-stock.aspx", "image": "https://g.foolcdn.com/image/?url=http%3A%2F%2Fg.foolcdn.com%2Fassets%2Fimages%2Ffool%2Ftmf-logo.png&h=630&w=1200&op=resize", "type": "article"}, "headline": "Zogenix: Time to Buy This Battleground Stock?", "fb": {"admins": 50808187550, "page_id": 7240312795, "app_id": 50808187550}, "bureau": "usmf-health-care", "STORY_UID": "ab6b913c-082d-11e4-9db5-0050569d4be0", "pitch": 823, "date": "2014-07-10T21:00:00Z", "gsa_date": "2014 07 10", "tickers": "ZGNX", "viewport": "width=device-width, initial-scale=1.0, maximum-scale=1.0"}, "_id": "\"57477af46914bd0286fd7ed6\"", "article_summary": "In the video below, Motley Fool health care analysts Michael Douglass and David Williamson give their take.\nZogenix (NASDAQ:ZGNX) shareholders have had a roller coaster ride in 2014, with the share price climbing to almost $5 per share before cratering below $1.70.\nThe big question: Has all the negativity been priced in already, or is this stock still one to avoid?\nTremendous controversy has swirled around Zohydro ER, an opioid painkiller that many fear could be abused.\nThe company received good news when Massachusetts Governor Deval Patrick's regulations to restrict the drug's usage were overturned by a federal court, and announced further good news that it may have a more tamper-resistant version of the drug out by 2015."}